AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
As of today, AbbVie(ABBV) shares are valued at $261.64. The company's market cap stands at 462.6B, with a P/E ratio of 74.44 and a dividend yield of 2.59%.
During the trading session on 2026-09-30, AbbVie(ABBV) shares reached a daily high of $265.16 and a low of $261.59. At a current price of $261.64, the stock is +0.0% higher than the low and still -1.3% under the high.
Trading activity shows a volume of 4.26M, compared to an average daily volume of 3.89M.
The stock's 52-week range extends from a low of $190.75 to a high of $269.39.
The stock's 52-week range extends from a low of $190.75 to a high of $269.39.
ABBV News
...
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie has completed a Phase 1 study called “A Phase 1 Study to Evaluate the Effect of Itrac...
AbbVie (NYSE:ABBV) reported positive Phase 2 outcomes for zumilokibart in atopic dermatitis at EADV 2026 in Berlin. The firm said zumilokibart has been selecte...
Analyst ratings
75%
of 32 ratingsMore ABBV News
AbbVie (ABBV) announced that detailed results from the multiple ascending dose part of its Phase 1 study evaluating ABBV-295 will be presented in a short oral p...
AbbVie (ABBV) announced that the primary results from the ongoing Phase 2 APEX Part B Dose-Regimen-Finding Study, evaluating zumilokibart, in adult patients wit...
(RTTNews) - AbbVie (ABBV) reported positive results from the Phase 2 APEX Part B study of zumilokibart, in adults with moderate to severe atopic dermatitis. Al...
When seeking reliable dividend payouts, look no further than the Dividend Kings. Several members of the elite club, including Johnson & Johnson (JNJ Quick Quote...
On CNBC’s “Halftime Report Final Trades,” Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, picked UnitedHealth Grou...
AbbVie (ABBV) is investing in its AI infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at w...
BofA analyst Tim Anderson raised the firm’s price target on AbbVie (ABBV) to $289 from $282 and keeps a Buy rating on the shares. The company is well positioned...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.